Denmark
Denmark

Time filter

Source Type

Hoersholm, Denmark, May 17th, 2017 - Medical Prognosis Institute A/S ("MPI") today announced that the previously warranted abstract with DRP data on epirubicin for breast cancer has been published electronically on the website of ASCO (American Society of Clinical Oncology). The title of the abstract is "Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort".  The DRP was significantly associated to Progression Free Survival (PFS) in a cohort of 137 metastatic breast cancer patients. PFS is a measure of the total time epirubicin can block tumor growth. The estimated median time to progression for a patient with a DRP value of 25% was 7 months versus 13 months for a patient with a DRP value of 75%. The result is of tremendous value to MPI as epirubicin response prediction is an important part of building a broader Patient Response Prediction (PRP(TM)) Compass for individual patients and also for Oncology Ventures spinout 2X Oncology Inc. in developing the GSH-liposomal- doxorubicin for breast and brain cancer with their in-licensed product 2X-111. MPI will own 10% of 2X Oncology Inc. after a successful series A financing. The poster including update of data will be presented on the 4th of June 2017 at the annual ASCO conference in Chicago, USA taking place from June 2-6 2017. Epirubicin - which is an anthracycline like doxorubicin - is a cornerstone in the treatment of primary and advanced breast cancer. Usually about 50% will benefit with a reduction in their tumor size. Until now there has been no method to find out who will benefit and who will not. The current study looked at 137 epirubicin treated patients to evaluate MPI's Epirubicin Drug Response Predictor (DRP(TM)). The DRP was significantly associated to Progression Free Survival (PFS) that measures the total time epirubicin can block tumor growth. The estimated median time to progression for a patient with a DRP value of 25% was 7 months versus 13 months for a patient with a DRP value of 75%. The result is of tremendous value to MPI as epirubicin response prediction is an important part of building a broader Patient Response Prediction (PRP(TM)) Compass for individual patients and also for Oncology Ventures spinout 2X Oncology Inc. in developing the GSH-liposomal- doxorubicin for breast and brain cancer with their in-licensed product 2X-111.  MPI will own 10% of 2X Oncology Inc. after a successful series A financing. "These data are of great importance to MPI as our patented Epirubicin DRP(TM) is now with statistically significance validated also in clinical practice. 2X Oncology Inc.'s product 2X-111 is very similar to epirubicin- and I am confident that by using the DRP(TM) to analyze the individual patient's tumor we can find those patients who are most likely to benefit from 2X-111. Anthracyclines are cornerstone products for treating breast cancer patients all over the world. Further to this the new published data strengthen MPI's Personalized Response Predictor - an oncology drug compass for the individual patient.", said Adjunct Professor Peter Buhl Jensen, M.D., CEO of MPI. "MPI  will own 10% of 2X Oncology Inc. after a successful series A financing," Peter Buhl Jensen further commented. Earlier this year (24th of January 2017) Medical Prognosis Institute and Oncology Venture published information on data based on more than 800 patients with metastatic breast cancer that demonstrated with statistical significant values that the Patient Response Predictor (PRP) could predict whether the individual patients would respond on the treatment with epirubicin (an anthracycline like doxorubicin), fulvestrant, anastrazole and exemestan or not. As there is a high number of active anticancer agents for Breast Cancer and this approach has been very fruitful, MPI and Oncology Venture will continue to broaden the database and the data mining to increase the number of products where our DRP technology can bring value to the choice of therapy. The abstract will be released by ASCO on May 17, 2017, at 5:00 PM EDT/23:00 CET on abstracts.asco.org An up-date on data from the abstract will be presented as a poster on the poster session Breast Cancer-Metastatic on the 4th of June 2017 at 8:00 AM-11:30 AM local time/15:00-18:30 CET. ASCO, American Society of Clinical Oncology, ANNUAL MEETING. McCormick Place, Chicago, Illinois, USA. Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. The ASCO Annual Meeting is considered the premiere international forum for the presentation of scientific research and state-of-the-art education in clinical oncology. The five-day event attracts 30,000 attendees from around the world. Clinical trial results and updates presented at ASCO's Annual Meeting represent the significant progress made each year in the fight against cancer. For further information on Oncology Venture please contact This information is that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 17th 2017. About the DRP(TM) Companion Diagnostic Developed by and in-licensed from Medical Prognosis Institute, the DRP(TM) screening platform utilizes messenger RNA (mRNA) gene expression signatures from patient biopsies to identify patients with a high likelihood of responding to specific cancer-fighting therapies. This DRP(TM) method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines, combined with clinical tumor biology and clinical correlates in a systems biology network. Specific DRP(TM)'s are developed for each pipeline product, which will enable us to identify and predict which patients are most likely to respond and thereby benefit from a given pipeline product.  This would enable likely responders to receive appropriate treatment while expediting the decision path for predicted non-responders, saving them critical time and money in their cancer fight. About Oncology Venture Sweden AB (OV) OV is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction - DRP(TM) - in order to significantly increase the probability of success in clinical trials. DRP(TM) has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients' tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient. The current product portfolio: LiPlaCis for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 - an immuno-oncology product for Multiple Myeloma. Oncology Venture has spun out 2X Oncology Inc. a company focused on developing precision medicine for women's cancer with three anticancer products in pipeline and OV-SPV2 which will test and potentially develop an oral Tyrosine Kinase inhibitor from a Big Pharma the treatment of cancers. About MPI's multiple biomarker called Drug Response Predictor - DRP(TM) MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US. About MPI Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark. For further information, please contact: CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD                              Ulla Hald Buhl, IR & Communication E-mail: pbj@medical-prognosis.com                                                          E-mail: uhb@medical-prognosis.com Telephone: +45 21 60 89 22                                                                                        Telephone +45 21 70 10 49 This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 17th 2017.


News Article | May 29, 2017
Site: globenewswire.com

Hoersholm; May 29th, 2017 - Medical Prognosis Institute (MPI:ST) today announced that Oncology Venture a spinout from MPI using MPI's DRP technology for drug development was informed by the US Patent Office that it will allow the claims in a patent application for a response predictor (DRP(TM)) for Oncology Ventures anticancer drug Irofulven. A patent will be issued by the US Patent Office in the near future. The Orange Book allows listing of biomarker patents that are required for the screening of patients for treatment with a specific drug. After that, a generic drug cannot be filed to replace Irofulven for as long as the biomarker patent is valid. "The granting of the patent on Irofulven in combination with its DRP is supporting MPI's patent strategy as Irofulven is now protected by for 20 years by the listing in the FDA Orange Book," Peter Buhl Jensen, M.D., CEO of MPI commented. Oncology Venture is developing the phase 2 drug candidate Irofulven, together with a companion diagnostic technology (Irofulven DRP(TM)) to identify patients highly likely to respond to Irofulven therapy. The Irofulven DRP(TM) companion diagnostic is derived from the Drug Response Predictor (DRP(TM)) Platform of Medical Prognosis Institute (MPI) and out-licensed to OV. Previous substantial clinical investigations in 38 clinical trials (19 published) of Irofulven by US biotech company MGI Pharma and pharmaceutical company Eisai led to objective responses in subsets of patients, including for a range of hard to treat cancers; such as prostate, ovarian, liver and pancreatic cancer. Utilizing the DRP Platform, genetic signatures have been identified associated with response to Irofulven. About The Orange Book The Orange Book identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. The Orange Book lists patents that are purported to protect each drug. Patent listings and use codes are provided by the drug application owner, and the FDA is obliged to list them. In order for a generic drug manufacturer to win approval of a drug under the Hatch-Waxman Act, the generic manufacturer must certify that they will not launch their generic until after the expiration of the Orange Book-listed patent, or that the patent is invalid, unenforceable, or that the generic product will not infringe the listed patent. About Irofulven Irofulven (6-hydroxymethylacylfulvene) is a semi-synthetic derivative of illudin S, a natural toxin isolated from the Jack O'lantern mushroom (Omphalotus illudens). A pro-drug, Irofulven requires catalysis by prostaglandin reductase 1 to become active. Created at the University of California, San Diego (UCSD), Irofulven was exclusively licensed to US biotech company MGI Pharma, which was acquired by Eisai in 2007.  After being returned to UCSD in 2009, Lantern Pharma licensed Irofulven in 2015, and subsequently sub-licensed Irofulven to Oncology Venture. Irofulven is more active in vitro against tumour cells of epithelial origin and is more resistant than other alkylating agents to deactivation by p53 loss and MDR1. Irofulven exhibits impressive anti-cancer results in xenograft models in vivo, shows synergy with topoisomerase I inhibitors, and has demonstrated activity against cell lines that are resistant to other therapies. Irofulven has significant scope for combination with other therapies, including standard chemotherapeutic regimes. About MPI's multiple biomarker called Drug Response Predictor - DRP(TM) MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 70 anti-cancer drugs in the US. About MPI Medical Prognosis Institute a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark. * Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level. A. M. F. Verschoor et al.  Published online: 12 August 2016 Springer Science+Business Media New York 2016 For further information, please contact: CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.D.                              Ulla Hald Buhl, IR & Communication E-mail: pbj@medical-prognosis.com                                                            E-mail: uhb@medical-prognosis.com Telephone: +45 21 60 89 22                                                                         Telephone +45 21 70 10 49 This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 29th, 2017.


News Article | May 29, 2017
Site: globenewswire.com

Hoersholm; May 29th, 2017 - Medical Prognosis Institute (MPI:ST) today announced that Oncology Venture a spinout from MPI using MPI's DRP technology for drug development was informed by the US Patent Office that it will allow the claims in a patent application for a response predictor (DRP(TM)) for Oncology Ventures anticancer drug Irofulven. A patent will be issued by the US Patent Office in the near future. The Orange Book allows listing of biomarker patents that are required for the screening of patients for treatment with a specific drug. After that, a generic drug cannot be filed to replace Irofulven for as long as the biomarker patent is valid. "The granting of the patent on Irofulven in combination with its DRP is supporting MPI's patent strategy as Irofulven is now protected by for 20 years by the listing in the FDA Orange Book," Peter Buhl Jensen, M.D., CEO of MPI commented. Oncology Venture is developing the phase 2 drug candidate Irofulven, together with a companion diagnostic technology (Irofulven DRP(TM)) to identify patients highly likely to respond to Irofulven therapy. The Irofulven DRP(TM) companion diagnostic is derived from the Drug Response Predictor (DRP(TM)) Platform of Medical Prognosis Institute (MPI) and out-licensed to OV. Previous substantial clinical investigations in 38 clinical trials (19 published) of Irofulven by US biotech company MGI Pharma and pharmaceutical company Eisai led to objective responses in subsets of patients, including for a range of hard to treat cancers; such as prostate, ovarian, liver and pancreatic cancer. Utilizing the DRP Platform, genetic signatures have been identified associated with response to Irofulven. About The Orange Book The Orange Book identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. The Orange Book lists patents that are purported to protect each drug. Patent listings and use codes are provided by the drug application owner, and the FDA is obliged to list them. In order for a generic drug manufacturer to win approval of a drug under the Hatch-Waxman Act, the generic manufacturer must certify that they will not launch their generic until after the expiration of the Orange Book-listed patent, or that the patent is invalid, unenforceable, or that the generic product will not infringe the listed patent. About Irofulven Irofulven (6-hydroxymethylacylfulvene) is a semi-synthetic derivative of illudin S, a natural toxin isolated from the Jack O'lantern mushroom (Omphalotus illudens). A pro-drug, Irofulven requires catalysis by prostaglandin reductase 1 to become active. Created at the University of California, San Diego (UCSD), Irofulven was exclusively licensed to US biotech company MGI Pharma, which was acquired by Eisai in 2007.  After being returned to UCSD in 2009, Lantern Pharma licensed Irofulven in 2015, and subsequently sub-licensed Irofulven to Oncology Venture. Irofulven is more active in vitro against tumour cells of epithelial origin and is more resistant than other alkylating agents to deactivation by p53 loss and MDR1. Irofulven exhibits impressive anti-cancer results in xenograft models in vivo, shows synergy with topoisomerase I inhibitors, and has demonstrated activity against cell lines that are resistant to other therapies. Irofulven has significant scope for combination with other therapies, including standard chemotherapeutic regimes. About MPI's multiple biomarker called Drug Response Predictor - DRP(TM) MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 70 anti-cancer drugs in the US. About MPI Medical Prognosis Institute a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark. * Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level. A. M. F. Verschoor et al.  Published online: 12 August 2016 Springer Science+Business Media New York 2016 For further information, please contact: CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.D.                              Ulla Hald Buhl, IR & Communication E-mail: pbj@medical-prognosis.com                                                            E-mail: uhb@medical-prognosis.com Telephone: +45 21 60 89 22                                                                         Telephone +45 21 70 10 49 This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 29th, 2017.


News Article | May 29, 2017
Site: globenewswire.com

Hoersholm; May 29th, 2017 - Medical Prognosis Institute (MPI:ST) today announced that Oncology Venture a spinout from MPI using MPI's DRP technology for drug development was informed by the US Patent Office that it will allow the claims in a patent application for a response predictor (DRP(TM)) for Oncology Ventures anticancer drug Irofulven. A patent will be issued by the US Patent Office in the near future. The Orange Book allows listing of biomarker patents that are required for the screening of patients for treatment with a specific drug. After that, a generic drug cannot be filed to replace Irofulven for as long as the biomarker patent is valid. "The granting of the patent on Irofulven in combination with its DRP is supporting MPI's patent strategy as Irofulven is now protected by for 20 years by the listing in the FDA Orange Book," Peter Buhl Jensen, M.D., CEO of MPI commented. Oncology Venture is developing the phase 2 drug candidate Irofulven, together with a companion diagnostic technology (Irofulven DRP(TM)) to identify patients highly likely to respond to Irofulven therapy. The Irofulven DRP(TM) companion diagnostic is derived from the Drug Response Predictor (DRP(TM)) Platform of Medical Prognosis Institute (MPI) and out-licensed to OV. Previous substantial clinical investigations in 38 clinical trials (19 published) of Irofulven by US biotech company MGI Pharma and pharmaceutical company Eisai led to objective responses in subsets of patients, including for a range of hard to treat cancers; such as prostate, ovarian, liver and pancreatic cancer. Utilizing the DRP Platform, genetic signatures have been identified associated with response to Irofulven. About The Orange Book The Orange Book identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. The Orange Book lists patents that are purported to protect each drug. Patent listings and use codes are provided by the drug application owner, and the FDA is obliged to list them. In order for a generic drug manufacturer to win approval of a drug under the Hatch-Waxman Act, the generic manufacturer must certify that they will not launch their generic until after the expiration of the Orange Book-listed patent, or that the patent is invalid, unenforceable, or that the generic product will not infringe the listed patent. About Irofulven Irofulven (6-hydroxymethylacylfulvene) is a semi-synthetic derivative of illudin S, a natural toxin isolated from the Jack O'lantern mushroom (Omphalotus illudens). A pro-drug, Irofulven requires catalysis by prostaglandin reductase 1 to become active. Created at the University of California, San Diego (UCSD), Irofulven was exclusively licensed to US biotech company MGI Pharma, which was acquired by Eisai in 2007.  After being returned to UCSD in 2009, Lantern Pharma licensed Irofulven in 2015, and subsequently sub-licensed Irofulven to Oncology Venture. Irofulven is more active in vitro against tumour cells of epithelial origin and is more resistant than other alkylating agents to deactivation by p53 loss and MDR1. Irofulven exhibits impressive anti-cancer results in xenograft models in vivo, shows synergy with topoisomerase I inhibitors, and has demonstrated activity against cell lines that are resistant to other therapies. Irofulven has significant scope for combination with other therapies, including standard chemotherapeutic regimes. About MPI's multiple biomarker called Drug Response Predictor - DRP(TM) MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 70 anti-cancer drugs in the US. About MPI Medical Prognosis Institute a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark. * Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level. A. M. F. Verschoor et al.  Published online: 12 August 2016 Springer Science+Business Media New York 2016 For further information, please contact: CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.D.                              Ulla Hald Buhl, IR & Communication E-mail: pbj@medical-prognosis.com                                                            E-mail: uhb@medical-prognosis.com Telephone: +45 21 60 89 22                                                                         Telephone +45 21 70 10 49 This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 29th, 2017.


News Article | May 29, 2017
Site: globenewswire.com

Hoersholm; May 29th, 2017 - Medical Prognosis Institute (MPI:ST) today announced that Oncology Venture a spinout from MPI using MPI's DRP technology for drug development was informed by the US Patent Office that it will allow the claims in a patent application for a response predictor (DRP(TM)) for Oncology Ventures anticancer drug Irofulven. A patent will be issued by the US Patent Office in the near future. The Orange Book allows listing of biomarker patents that are required for the screening of patients for treatment with a specific drug. After that, a generic drug cannot be filed to replace Irofulven for as long as the biomarker patent is valid. "The granting of the patent on Irofulven in combination with its DRP is supporting MPI's patent strategy as Irofulven is now protected by for 20 years by the listing in the FDA Orange Book," Peter Buhl Jensen, M.D., CEO of MPI commented. Oncology Venture is developing the phase 2 drug candidate Irofulven, together with a companion diagnostic technology (Irofulven DRP(TM)) to identify patients highly likely to respond to Irofulven therapy. The Irofulven DRP(TM) companion diagnostic is derived from the Drug Response Predictor (DRP(TM)) Platform of Medical Prognosis Institute (MPI) and out-licensed to OV. Previous substantial clinical investigations in 38 clinical trials (19 published) of Irofulven by US biotech company MGI Pharma and pharmaceutical company Eisai led to objective responses in subsets of patients, including for a range of hard to treat cancers; such as prostate, ovarian, liver and pancreatic cancer. Utilizing the DRP Platform, genetic signatures have been identified associated with response to Irofulven. About The Orange Book The Orange Book identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. The Orange Book lists patents that are purported to protect each drug. Patent listings and use codes are provided by the drug application owner, and the FDA is obliged to list them. In order for a generic drug manufacturer to win approval of a drug under the Hatch-Waxman Act, the generic manufacturer must certify that they will not launch their generic until after the expiration of the Orange Book-listed patent, or that the patent is invalid, unenforceable, or that the generic product will not infringe the listed patent. About Irofulven Irofulven (6-hydroxymethylacylfulvene) is a semi-synthetic derivative of illudin S, a natural toxin isolated from the Jack O'lantern mushroom (Omphalotus illudens). A pro-drug, Irofulven requires catalysis by prostaglandin reductase 1 to become active. Created at the University of California, San Diego (UCSD), Irofulven was exclusively licensed to US biotech company MGI Pharma, which was acquired by Eisai in 2007.  After being returned to UCSD in 2009, Lantern Pharma licensed Irofulven in 2015, and subsequently sub-licensed Irofulven to Oncology Venture. Irofulven is more active in vitro against tumour cells of epithelial origin and is more resistant than other alkylating agents to deactivation by p53 loss and MDR1. Irofulven exhibits impressive anti-cancer results in xenograft models in vivo, shows synergy with topoisomerase I inhibitors, and has demonstrated activity against cell lines that are resistant to other therapies. Irofulven has significant scope for combination with other therapies, including standard chemotherapeutic regimes. About MPI's multiple biomarker called Drug Response Predictor - DRP(TM) MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 70 anti-cancer drugs in the US. About MPI Medical Prognosis Institute a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark. * Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level. A. M. F. Verschoor et al.  Published online: 12 August 2016 Springer Science+Business Media New York 2016 For further information, please contact: CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.D.                              Ulla Hald Buhl, IR & Communication E-mail: pbj@medical-prognosis.com                                                            E-mail: uhb@medical-prognosis.com Telephone: +45 21 60 89 22                                                                         Telephone +45 21 70 10 49 This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 29th, 2017.


News Article | April 10, 2017
Site: globenewswire.com

CORRECTED version includes the amount of the loss. Der indkaldes herved til EKSTRAORDINÆR generalforsamling i Medical Prognosis Institute A/S ("Selskabet"): Notice is hereby given that aN EXTRAORDINARY general meeting of Medical Prognosis Institute A/S (the "Company") will be held on: Generalforsamlingen afholdes hos: The general meeting will be held at: Dagsorden for generalforsamlingen er som følger: The agenda for the annual general meeting is as follows: 1.                   Valg af dirigent.                       Election of Chairman of the Meeting 2.                   Beretning om selskabets virksomhed i det forløbne år.                       Report on the Company's activities during the past year. 3.                   Fremlæggelse af årsrapport med revisionspåtegning til godkendelse. Presentation of audited annual report with Auditor's statement for approval 4.                   Beslutning om anvendelse af overskud eller dækning af tab i henhold til den godkendte årsrapport.                       Resolution on application of profits or covering of losses as per the adopted annual report. 7.                   Forslag fra bestyrelsen                       Proposals from the board of directors and/or shareholders 7.1.               Forslag om ændring af selskabets vedtægter, vedrørende:                       Proposal to amend the articles of association: 7.1.1.            Tilretning af §6.1 om bemyndigelse til bestyrelsen til at udstede warrants. Forslaget medfører ikke indholdsmæssige ændringer. Amendment  of §6.1 regarding authorization to the Board of Directors to issue warrants. The proposal does not entail any changes with regards to the content of the articles. 7.1.2             Justering af bemyndigelse til bestyrelsen til at fortage kapitalforhøjelser med fortegningsret for selskabets aktionærer.                          Adjusting of the authorization to the Board of Directors to increase the share capital of the Company with pre-emptive subscription right for existing shareholders. 7.1.3.            Ændring af § 8.4 om anvendelse af dansk eller engelsk sprog i forbindelse med generalforsamlinger og indkaldelser til disse Amendment of §8.4 regarding Danish or English language in connection with general meetings and convening notices 7.1.4.            Ændring af § 8.6 om adgangskrav ved afholdelse af generalforsamlinger                       Amendment of §8.6 regarding conditions for access to general meetings 7.1.5.            Ny § 12.3 om Dansk eller engelsk sprog på bestyrelsesmøder New §12.3 regarding Danish or English language on Board of Directors meetings. 7.1.6             Indsættelse af engelsk oversættelse af vedtægternes bestemmelser. Implementing of an English language translation of the articles of association. 8.                   Forslag om bemyndigelse til dirigenten                       Proposal to authorize the chairman of the meeting Re 1 Bestyrelsen foreslår, at advokat Lars Lüthjohan Jensen vælges som dirigent på generalforsamlingen. The Board of Directors proposes that attorney-at-law Lars Lüthjohan Jensen is elected as chairman of the general meeting. Re 2 Formanden for bestyrelsen og/eller den administrerende direktør vil berette om selskabets virksomhed i det forløbne år. Chairman of the Board, and / or Chief Executive Officer will report on the Company's activities for the year ended December 31, 2016. Bestyrelsen foreslår at den reviderede årsrapport godkendes The Board of Directors recommends that the audited annual report will be adopted. Bestyrelsen foreslår at det konsoliderede tab for regnskabsåret 2016 på 8.729.384 overføres til næste år ved indregning i overført resultat. The Board of Directors proposes that the consolidated loss for the year of 8,729,384 be carried forward to next year through recognition in retained earnings. Den samlede nuværende bestyrelse er på valg. I henhold til Selskabets vedtægter skal bestyrelsen bestå af 3-5 medlemmer. All Members of the Board of Directors are up for election. Pursuant to the Articles of Association, the Board of Directors shall consist of 3-5 members. Den nuværende bestyrelse består af følgende bestyrelsesmedlemmer: Currently, the Board of Directors is composed of the following: that article 12 of the articles of association is amended, so that the board of directors shall consist of 3-6 members and not 3-5 members. that all members of the Board of Directors are re-elected and that Jørgen Bardenfleth is elected so that the Board of Directors will consist of the following members: Samtlige ovenstående personer har tilbudt at stille op til valg eller genvalg. Information om de nuværende bestyrelsesmedlemmer er tilgængelig på selskabets hjemmeside. All persons above have offered themselves for reelection or election. Information about the current board members is available on the Company's website. The Board of Directors proposes that, Forslag fra bestyrelsen Proposals from the Board of Directors Med henblik på at sikre, at Selskabets vedtægter fremstår sammenhængende og forståelige samt med henblik på at sikre, at Selskabets vedtægter indeholder hensigtsmæssige bestemmelser om den praktiske gennemførelses af generalforsamlinger og bestyrelsesmøder, fremsætter bestyrelsen følgende forslag om ændringer i Selskabets vedtægter: To ensure that the Company's articles of association are coherent and easily understood, and to ensure that the Articles of Association contain appropriate provisions regarding the conduct of general meetings and Board of Directors meetings, The Board of Directors proposes the following amendments of the Articles of Association: Re 7.1.1 - Bestyrelsen foreslår følgende tilretninger i vedtægternes § 6.1. Forslaget medfører ikke indholdsmæssige ændringer. Det foreslås at det nuværende 3. afsnit i § 6.1 rykkes og fremover udgør et nyt afsnit 6.2, samt at det nuværende 4. afsnit i § 6.1 rykkes, således at afsnittet fremover er første afsnit i § 6.1, således at § 6.1 fremover har følgende ordlyd: The Board of Directors proposes the following amendments of articles 6.1 in the articles of association. No changes are intended as regard to the content. The Board of Directors proposes that the 3rd section of the current § 6.1 is moved to a new § 6.3 and that the 4th section of the current § 6.1 is moved so that the section will be the first section of § 6.1, so that the wording of § 6.1 will be as follows: "6.1 Generalforsamlingen har den 24. april 2014 besluttet at bemyndige bestyrelsen til ad en eller flere omgange at træffe beslutning om udstedelse af warrants til tegning af aktier på et nominelt beløb op til kr. 95.000 samt til at træffe beslutning om den dertil hørende kapitalforhøjelse. Udstedelse af warrants kan ske til selskabets nøglemedarbejdere, bestyrelsesmedlemmer og andre nøglepersoner, og således uden fortegningsret for eksisterende aktionærer. Udstedelsen af warrants kan ske til en udnyttelseskurs som fastsættes af bestyrelsen. Aktier, der tegnes ved udnyttelse af warrants, skal have de samme rettigheder som eksisterende aktier i selskabet, jf. vedtægternes til enhver tid gældende bestemmelse herom. De nye aktier skal være omsætningspapirer og skal lyde på navn. Øvrige vilkår for warrants fastsættes af bestyrelsen i forbindelse med bestyrelsens udnyttelse af bemyndigelsen. Bemyndigelsen gives for en periode på 5 år og udløber den 24. april 2019. På et bestyrelsesmøde i Selskabet afholdt den 17. december 2014 vedtog Selskabets bestyrel-se at udstede warrants svarende til nominelt DKK 28.500 aktier; og bestyrelsen vedtog samti-dig at forhøje Selskabets aktiekapital i overensstemmelse dermed. De fuldstændige vilkår for warrants er vedlagt som bilag 3. Bilag 3 udgør en integreret del af nærværende vedtægter. På et bestyrelsesmøde i Selskabet afholdt den 18. februar 2016 vedtog Selskabets bestyrelse at udstede warrants svarende til nominelt DKK 31.689 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. De fuldstændige vilkår for warrants er vedlagt som bilag 4. Bilag 4 udgør en integreret del af nærværende vedtægter. Som nyt § 6.2 indsætte følgende: "6.2. Generalforsamlingen har den 24. februar 2017 vedtaget at udstede 430.000 warrants sva-rende til nominelt kr. 21.500 på vilkår som anført i bilag 3, dog således at tildelte warrants er fuldt optjente på tildelingstidspunktet, samt 266.220 warrants svarende til nominelt kr. 13.311 på vilkår som anført i bilag 4, dog således at tildelte warrants optjenes med 1/36 fra 1. juli 2016." Re 7.1.2.- Bestyrelsen foreslår, at den i selskabets vedtægter § 7.1 indeholdte bemyndigelse til bestyrelsen til at fortage kapitalforhøjelser med fortegningsret for selskabets aktionærer justeres, således at bestyrelsen bemyndiges i perioden indtil den 1. april 2022 til ad en eller flere gange at forhøje selskabets aktiekapital ved udstedelse af nye aktier med indtil nominelt DKK 200.000. The Board of Directors proposes that the authorization in article 7.1 in the articles of association to the Board of Directors to, at one of more times, increase the share capital of the company with preemptive subscription right for the existing shareholders is adjusted, so that the Board of Directors are authorized to increase the share capital of the company by issuing new share with up to nominal DKK 200,000. Re 7.1.3.-       Bestyrelsen foreslår, at § 8.4 ændres, således at det fremgår, at sproget på selskabets generalforsamlinger og i generalforsamlingsindkaldelser er engelsk. Ordlyden i § 8.4 vil herefter være: The Board of Directors proposes that § 8.4 of the articles of association is amended, so that the article states that English language will be used at general meetings and in convening notices. "8.4. Selskabets generalforsamlinger afholdes på selskabets hjemsted eller i hovedstadsområ-det. Der anvendes engelsk sprog på selskabets generalforsamlinger og i forbindelse med indkaldelse til disse. Der kan på den enkelte generalforsamling træffes beslutning om, at generalforsamling afholdes på dansk." Re 7.1.4.- Bestyrelsen foreslår, at følgende indsættes som ny § 8.6, der erstatter den nuværende § 8.6: The Board of Directors proposes that the following wording is obtained as a new § 8.6 replacing the existing § 8.6. Re 7.1.5.-       Bestyrelsen foreslår, at følgende bestemmelse indsættes som ny § 12.3: The Board of Directors proposes that the following provision is obtained as new § 12.3: Re 7.1.6.- Bestyrelsen foreslår, at bestyrelsen bemyndiges til at udfærdige en engelsk oversættelse af vedtægterne, således at selskabets vedtægter fremover forelægger både på dansk og engelsk. The Board of Directors proposes that the Board of Directors is authorized to translate the articles of association to English language so that the articles of association are kept both in Danish and English. Vedtagelseskrav: Voting requirements for adoption: Der gælder følgende vedtagelseskrav for forslagene, der skal være opfyldte for, at forslagene kan anses som vedtaget: The following voting requirements apply to the adoption of the proposals:                       Forslagene under punkt (**) kan vedtages med simpelt flertal. The proposals in item (**) require simple majority of the votes cast. Forslagene under punkt (**) kan vedtages med et flertal på mindst 2/3 af de afgivne stemmer og af den på generalforsamlingen repræsenterede kapital. The proposals in items (**) require a majority in favor of the proposed resolution of at least two thirds of both the votes cast and of the voting share capital represented at the general meeting. Information: Information: Denne indkaldelse indeholdende dagsorden og de fuldstændige forslag vil være fremlagt på selskabets kontor til eftersyn og vil være tilgængelige på Selskabets hjemmeside www.medical-prognosis.com fra dags dato. This notice including agenda and the complete proposals will be available for review the Company's premises as well as on the Company's web page www.medical-prognosis.com from today. En aktionærs ret til at deltage i og stemme på den ekstraordinære generalforsamling fastlægges på baggrund af de aktier, som aktionæren besidder på registreringsdagen tirsdag den 18. april 2017  i henhold til selskabets ejerbog. Selskabets ejerbog føres af VP Securities A/S. Aktier skal være noteret på navn i ejerbogen ført af VP Securities A/S eller være noteret på navn hos Euroclear Sweden AB. Aktionærer der ejer aktier gennem en depotbank skal koordinere med depotbanken, at aktionæren bliver noteret på navn hos Euroclear Sweden AB forud for generalforsamlingen.  The right of a shareholder to attend and vote at the extraordinary general meeting is determined by the shares held by the shareholder at the registration date 18 April 2017 according to the shareholder register kept by VP Securities A/S. The shareholder must be recorded by name in the shareholder register kept by VP Securities A/S and by Euroclear Sweden AB. Shareholders who hold shares through a depositary bank shall coordinate with their depositary bank that the shareholder is duly registered by name with Euroclear Sweden AB prior to the general meeting. Afgivelse af fuldmagt Aktionærer kan stemme ved fuldmagt. Som bilag til denne indkaldelse er indeholdt en fuldmagtsblanket, som kan anvendes såfremt aktionærer ønsker at give fuldmagt til bestyrelsen. For the general meeting, shareholders may vote by proxy. A proxy form is attached to this notice and can be downloaded from the website of the Company, www.medical-prognosis.com Brevstemmer: Aktionærer er berettigede til - som alternativ til at give møde og stemme på selve generalforsamlingen - at brevstemme, dvs. afgive skriftlig stemme før afholdelsen af generalforsamlingen. Aktionærer, der ønsker at brevstemme, skal sende deres brevstemme til Selskabet således at denne er modtaget af selskabet senest kl. 12.00 den (**). Brevstemmer kan ikke tilbagekaldes. Vær opmærksom på at breve undertiden kan være flere dage undervejs. Shareholders may - instead of voting in person at the ordinary general meeting - choose to vote by mail, i.e. voting in writing prior to the general meeting. Any shareholder who chooses to vote by mail shall send the absentee vote to the Company so that the has Company receives the votes at the latest on February (**) at 12:00 am. Votes delivered by mail cannot be revoked. Please take into account that mail can be several days in transfer. -oo0oo- April 10, 2017 On behalf of the Board of Directors Fuldmagt til at repræsentere og afgive stemme for min samlede aktiebeholdning på den ekstraordinære generalforsamling i Medical Prognosis Institute A/S, (**) 2017 Power of attorney to represent and vote on all my shares at the Extraordinary General Meeting of Medical Prognosis Institute A / S, (**) 2017 Returnér denne fuldmagt underskrevet og dateret til Medical Prognosis Institute A/S, venlighedsvej 1, DK -2970 Hørsholm. Please return the power of attorney signed and dated to Medical Prognosis Institute A/S, Venlighedsvej 1, DK - 2970 Hoersholm. For further information, please contact: CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.D.                    Ulla Hald Buhl, IR & Communication E-mail: pbj@medical-prognosis.com                                                    E-mail: uhb@medical-prognosis.com Telephone: +45 21 60 89 22                                                                 Telephone +45 21 70 10 49 This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 10th, 2017.


News Article | April 10, 2017
Site: globenewswire.com

Der indkaldes herved til EKSTRAORDINÆR generalforsamling i Medical Prognosis Institute A/S ("Selskabet"): Notice is hereby given that aN EXTRAORDINARY general meeting of Medical Prognosis Institute A/S (the "Company") will be held on: Generalforsamlingen afholdes hos: The general meeting will be held at: Dagsorden for generalforsamlingen er som følger: The agenda for the annual general meeting is as follows: 1.                   Valg af dirigent.                       Election of Chairman of the Meeting 2.                   Beretning om selskabets virksomhed i det forløbne år.                       Report on the Company's activities during the past year. 3.                   Fremlæggelse af årsrapport med revisionspåtegning til godkendelse.   Presentation of audited annual report with Auditor's statement for approval 4.                   Beslutning om anvendelse af overskud eller dækning af tab i henhold til den godkendte årsrapport.                       Resolution on application of profits or covering of losses as per the adopted annual report. 7.                   Forslag fra bestyrelsen                       Proposals from the board of directors and/or shareholders 7.1.               Forslag om ændring af selskabets vedtægter, vedrørende:                       Proposal to amend the articles of association: 7.1.1.            Tilretning af §6.1 om bemyndigelse til bestyrelsen til at udstede warrants. Forslaget medfører ikke indholdsmæssige ændringer.               Amendment  of §6.1 regarding authorization to the Board of Directors to issue warrants. The proposal does not entail any changes with regards to the content of the   articles. 7.1.2             Justering af bemyndigelse til bestyrelsen til at fortage kapitalforhøjelser med fortegningsret for selskabets aktionærer.                          Adjusting of the authorization to the Board of Directors to increase the share capital of the Company with pre-emptive subscription right for existing shareholders. 7.1.3.            Ændring af § 8.4 om anvendelse af dansk eller engelsk sprog i forbindelse med generalforsamlinger og indkaldelser til disse Amendment of §8.4 regarding Danish or English language in connection with general meetings and convening notices 7.1.4.            Ændring af § 8.6 om adgangskrav ved afholdelse af generalforsamlinger                       Amendment of §8.6 regarding conditions for access to general meetings 7.1.5.            Ny § 12.3 om Dansk eller engelsk sprog på bestyrelsesmøder   New §12.3 regarding Danish or English language on Board of Directors meetings. 7.1.6             Indsættelse af engelsk oversættelse af vedtægternes bestemmelser.  Implementing of an English language translation of the articles of association. 8.                   Forslag om bemyndigelse til dirigenten                       Proposal to authorize the chairman of the meeting Re 1 Bestyrelsen foreslår, at advokat Lars Lüthjohan Jensen vælges som dirigent på generalforsamlingen. The Board of Directors proposes that attorney-at-law Lars Lüthjohan Jensen is elected as chairman of the general meeting. Re 2 Formanden for bestyrelsen og/eller den administrerende direktør vil berette om selskabets virksomhed i det forløbne år. Chairman of the Board, and / or Chief Executive Officer will report on the Company's activities for the year ended December 31, 2016. Bestyrelsen foreslår at den reviderede årsrapport godkendes The Board of Directors recommends that the audited annual report will be adopted. Bestyrelsen foreslår at det konsoliderede tab for regnskabsåret 2016 på (**) The Board of Directors proposes that the consolidated loss for the year of (**) million be carried forward to next year through recognition in retained earnings. Den samlede nuværende bestyrelse er på valg. I henhold til Selskabets vedtægter skal bestyrelsen bestå af 3-5 medlemmer. All Members of the Board of Directors are up for election. Pursuant to the Articles of Association, the Board of Directors shall consist of 3-5 members. Den nuværende bestyrelse består af følgende bestyrelsesmedlemmer: Currently, the Board of Directors is composed of the following: that article 12 of the articles of association is amended, so that the board of directors shall consist of 3-6 members and not 3-5 members. that all members of the Board of Directors are re-elected and that Jørgen Bardenfleth is elected so that the Board of Directors will consist of the following members: Samtlige ovenstående personer har tilbudt at stille op til valg eller genvalg. Information om de nuværende bestyrelsesmedlemmer er tilgængelig på selskabets hjemmeside. All persons above have offered themselves for reelection or election. Information about the current board members is available on the Company's website. The Board of Directors proposes that, Forslag fra bestyrelsen Proposals from the Board of Directors Med henblik på at sikre, at Selskabets vedtægter fremstår sammenhængende og forståelige samt med henblik på at sikre, at Selskabets vedtægter indeholder hensigtsmæssige bestemmelser om den praktiske gennemførelses af generalforsamlinger og bestyrelsesmøder, fremsætter bestyrelsen følgende forslag om ændringer i Selskabets vedtægter: To ensure that the Company's articles of association are coherent and easily understood, and to ensure that the Articles of Association contain appropriate provisions regarding the conduct of general meetings and Board of Directors meetings, The Board of Directors proposes the following amendments of the Articles of Association: Re 7.1.1 - Bestyrelsen foreslår følgende tilretninger i vedtægternes § 6.1. Forslaget medfører ikke indholdsmæssige ændringer. Det foreslås at det nuværende 3. afsnit i § 6.1 rykkes og fremover udgør et nyt afsnit 6.2, samt at det nuværende 4. afsnit i § 6.1 rykkes, således at afsnittet fremover er første afsnit i § 6.1, således at § 6.1 fremover har følgende ordlyd: The Board of Directors proposes the following amendments of articles 6.1 in the articles of association. No changes are intended as regard to the content. The Board of Directors proposes that the 3rd section of the current § 6.1 is moved to a new § 6.3 and that the 4th section of the current § 6.1 is moved so that the section will be the first section of § 6.1, so that the wording of § 6.1 will be as follows: "6.1 Generalforsamlingen har den 24. april 2014 besluttet at bemyndige bestyrelsen til ad en eller flere omgange at træffe beslutning om udstedelse af warrants til tegning af aktier på et nominelt beløb op til kr. 95.000 samt til at træffe beslutning om den dertil hørende kapitalforhøjelse. Udstedelse af warrants kan ske til selskabets nøglemedarbejdere, bestyrelsesmedlemmer og andre nøglepersoner, og således uden fortegningsret for eksisterende aktionærer. Udstedelsen af warrants kan ske til en udnyttelseskurs som fastsættes af bestyrelsen. Aktier, der tegnes ved udnyttelse af warrants, skal have de samme rettigheder som eksisterende aktier i selskabet, jf. vedtægternes til enhver tid gældende bestemmelse herom. De nye aktier skal være omsætningspapirer og skal lyde på navn. Øvrige vilkår for warrants fastsættes af bestyrelsen i forbindelse med bestyrelsens udnyttelse af bemyndigelsen. Bemyndigelsen gives for en periode på 5 år og udløber den 24. april 2019. På et bestyrelsesmøde i Selskabet afholdt den 17. december 2014 vedtog Selskabets bestyrel-se at udstede warrants svarende til nominelt DKK 28.500 aktier; og bestyrelsen vedtog samti-dig at forhøje Selskabets aktiekapital i overensstemmelse dermed. De fuldstændige vilkår for warrants er vedlagt som bilag 3. Bilag 3 udgør en integreret del af nærværende vedtægter. På et bestyrelsesmøde i Selskabet afholdt den 18. februar 2016 vedtog Selskabets bestyrelse at udstede warrants svarende til nominelt DKK 31.689 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. De fuldstændige vilkår for warrants er vedlagt som bilag 4. Bilag 4 udgør en integreret del af nærværende vedtægter. Som nyt § 6.2 indsætte følgende: "6.2. Generalforsamlingen har den 24. februar 2017 vedtaget at udstede 430.000 warrants sva-rende til nominelt kr. 21.500 på vilkår som anført i bilag 3, dog således at tildelte warrants er fuldt optjente på tildelingstidspunktet, samt 266.220 warrants svarende til nominelt kr. 13.311 på vilkår som anført i bilag 4, dog således at tildelte warrants optjenes med 1/36 fra 1. juli 2016." Re 7.1.2.- Bestyrelsen foreslår, at den i selskabets vedtægter § 7.1 indeholdte bemyndigelse til bestyrelsen til at fortage kapitalforhøjelser med fortegningsret for selskabets aktionærer justeres, således at bestyrelsen bemyndiges i perioden indtil den 1. april 2022 til ad en eller flere gange at forhøje selskabets aktiekapital ved udstedelse af nye aktier med indtil nominelt DKK 200.000. The Board of Directors proposes that the authorization in article 7.1 in the articles of association to the Board of Directors to, at one of more times, increase the share capital of the company with preemptive subscription right for the existing shareholders is adjusted, so that the Board of Directors are authorized to increase the share capital of the company by issuing new share with up to nominal DKK 200,000. Re 7.1.3.-       Bestyrelsen foreslår, at § 8.4 ændres, således at det fremgår, at sproget på selskabets generalforsamlinger og i generalforsamlingsindkaldelser er engelsk. Ordlyden i § 8.4 vil herefter være: The Board of Directors proposes that § 8.4 of the articles of association is amended, so that the article states that English language will be used at general meetings and in convening notices. "8.4. Selskabets generalforsamlinger afholdes på selskabets hjemsted eller i hovedstadsområ-det. Der anvendes engelsk sprog på selskabets generalforsamlinger og i forbindelse med indkaldelse til disse. Der kan på den enkelte generalforsamling træffes beslutning om, at generalforsamling afholdes på dansk." Re 7.1.4.- Bestyrelsen foreslår, at følgende indsættes som ny § 8.6, der erstatter den nuværende § 8.6: The Board of Directors proposes that the following wording is obtained as a new § 8.6 replacing the existing § 8.6. Re 7.1.5.-       Bestyrelsen foreslår, at følgende bestemmelse indsættes som ny § 12.3: The Board of Directors proposes that the following provision is obtained as new § 12.3: Re 7.1.6.- Bestyrelsen foreslår, at bestyrelsen bemyndiges til at udfærdige en engelsk oversættelse af vedtægterne, således at selskabets vedtægter fremover forelægger både på dansk og engelsk. The Board of Directors proposes that the Board of Directors is authorized to translate the articles of association to English language so that the articles of association are kept both in Danish and English. Vedtagelseskrav: Voting requirements for adoption: Der gælder følgende vedtagelseskrav for forslagene, der skal være opfyldte for, at forslagene kan anses som vedtaget: The following voting requirements apply to the adoption of the proposals:                       Forslagene under punkt (**) kan vedtages med simpelt flertal. The proposals in item (**) require simple majority of the votes cast. Forslagene under punkt (**) kan vedtages med et flertal på mindst 2/3 af de afgivne stemmer og af den på generalforsamlingen repræsenterede kapital. The proposals in items (**) require a majority in favor of the proposed resolution of at least two thirds of both the votes cast and of the voting share capital represented at the general meeting. Information: Information: Denne indkaldelse indeholdende dagsorden og de fuldstændige forslag vil være fremlagt på selskabets kontor til eftersyn og vil være tilgængelige på Selskabets hjemmeside www.medical-prognosis.com fra dags dato. This notice including agenda and the complete proposals will be available for review the Company's premises as well as on the Company's web page www.medical-prognosis.com from today. En aktionærs ret til at deltage i og stemme på den ekstraordinære generalforsamling fastlægges på baggrund af de aktier, som aktionæren besidder på registreringsdagen tirsdag den 18. april 2017  i henhold til selskabets ejerbog. Selskabets ejerbog føres af VP Securities A/S. Aktier skal være noteret på navn i ejerbogen ført af VP Securities A/S eller være noteret på navn hos Euroclear Sweden AB. Aktionærer der ejer aktier gennem en depotbank skal koordinere med depotbanken, at aktionæren bliver noteret på navn hos Euroclear Sweden AB forud for generalforsamlingen.  The right of a shareholder to attend and vote at the extraordinary general meeting is determined by the shares held by the shareholder at the registration date 18 April 2017 according to the shareholder register kept by VP Securities A/S. The shareholder must be recorded by name in the shareholder register kept by VP Securities A/S and by Euroclear Sweden AB. Shareholders who hold shares through a depositary bank shall coordinate with their depositary bank that the shareholder is duly registered by name with Euroclear Sweden AB prior to the general meeting. Afgivelse af fuldmagt Aktionærer kan stemme ved fuldmagt. Som bilag til denne indkaldelse er indeholdt en fuldmagtsblanket, som kan anvendes såfremt aktionærer ønsker at give fuldmagt til bestyrelsen. For the general meeting, shareholders may vote by proxy. A proxy form is attached to this notice and can be downloaded from the website of the Company, www.medical-prognosis.com Brevstemmer: Aktionærer er berettigede til - som alternativ til at give møde og stemme på selve generalforsamlingen - at brevstemme, dvs. afgive skriftlig stemme før afholdelsen af generalforsamlingen. Aktionærer, der ønsker at brevstemme, skal sende deres brevstemme til Selskabet således at denne er modtaget af selskabet senest kl. 12.00 den (**). Brevstemmer kan ikke tilbagekaldes. Vær opmærksom på at breve undertiden kan være flere dage undervejs. Shareholders may - instead of voting in person at the ordinary general meeting - choose to vote by mail, i.e. voting in writing prior to the general meeting. Any shareholder who chooses to vote by mail shall send the absentee vote to the Company so that the has Company receives the votes at the latest on February (**) at 12:00 am. Votes delivered by mail cannot be revoked. Please take into account that mail can be several days in transfer. -oo0oo- April 10, 2017 On behalf of the Board of Directors Fuldmagt til at repræsentere og afgive stemme for min samlede aktiebeholdning på den ekstraordinære generalforsamling i Medical Prognosis Institute A/S, (**) 2017 Power of attorney to represent and vote on all my shares at the Extraordinary General Meeting of Medical Prognosis Institute A / S, (**) 2017 Returnér denne fuldmagt underskrevet og dateret til Medical Prognosis Institute A/S, venlighedsvej 1, DK -2970 Hørsholm. Please return the power of attorney signed and dated to Medical Prognosis Institute A/S, Venlighedsvej 1, DK - 2970 Hoersholm. For further information, please contact: CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.D.                    Ulla Hald Buhl, IR & Communication E-mail: pbj@medical-prognosis.com                                                    E-mail: uhb@medical-prognosis.com Telephone: +45 21 60 89 22                                                                 Telephone +45 21 70 10 49 This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 10th, 2017.

Loading Hoersholm collaborators
Loading Hoersholm collaborators